News
The investors in ImmunityBio, Inc. 's ( NASDAQ:IBRX ) will be rubbing their hands together with glee today, after ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...
ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...
Zacks Investment Research on MSN2d
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue EstimatesImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago. These figures are ...
ImmunityBio, Inc.’s IBRX share price has surged by 10.14%, which has investors questioning if this is right time to sell.
Asianet Newsable on MSN8d
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s PositiveImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following ...
CULVER CITY, Calif., May 12, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028 ...
SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...
SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback